PTK7 and melanoma: Another revelation in melanoma research highlighted the potential of bromodomain inhibitors (BETi), emphasizing the critical role of the amphoterin-induced gene and open reading frame 2-protein tyrosine kinase 7 (AMIGO2-PTK7) pathway in their therapeutic impact [146].